Neuroendocrine Marker Expression in Primary Non-neuroendocrine
Epithelial Tumors of the Ovary: A Study of 551 Cases

J 2024

Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases

BÁRTŮ KENDALL, Michaela, Kristýna NĚMEJCOVÁ, Romana MICHÁLKOVÁ, Quang Hiep BUI, Jana DROZENOVÁ et. al.

Basic information

Original name

Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases

Authors

BÁRTŮ KENDALL, Michaela (203 Czech Republic), Kristýna NĚMEJCOVÁ (203 Czech Republic), Romana MICHÁLKOVÁ (203 Czech Republic), Quang Hiep BUI, Jana DROZENOVÁ (203 Czech Republic), Pavel FABIAN (203 Czech Republic), Oluwole FADARE, Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Jan LACO (203 Czech Republic), Radoslav MATĚJ (203 Czech Republic), Gábor MÉHES, Adam ŠAFANDA (203 Czech Republic), Naveena SINGH, Petr ŠKAPA (203 Czech Republic), Zuzana ŠPŮRKOVÁ (203 Czech Republic), Simona STOLNICU (203 Czech Republic), Marián ŠVAJDLER (203 Czech Republic), Sigurd F LAX, W Glenn MCCLUGGAGE and Pavel DUNDR (203 Czech Republic)

Edition

International Journal of Gynecological Pathology, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2024, 0277-1691

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.400 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1097/PGP.0000000000000962

UT WoS

001158920200003

Keywords in English

INSM1; Synaptophysin; Chromogranin; Immunohistochemistry; Ovarian Tumors

Abstract

V originále

Expression of neuroendocrine (NE) markers in primary ovarian non-NE epithelial tumors has rarely been evaluated. The aim of our study was to evaluate the expression of the most widely used NE markers in these neoplasms and to determine any prognostic significance of NE marker expression. The cohort consisted of 551 primary ovarian tumors, including serous borderline tumors, low-grade serous carcinomas, high-grade serous carcinomas (HGSC), clear cell carcinomas, endometroid carcinomas, mucinous borderline tumors, and mucinous carcinomas. Immunohistochemical analysis was performed using antibodies against INSM1, synaptophysin, chromogranin, and CD56 on tissue microarray. Positivity for INSM1, synaptophysin, chromogranin, and CD56 was most frequently observed in mucinous tumors (48.7%, 26.0%, 41.5%, and 100%, respectively). The positivity for these NE markers was mostly restricted to nonmucinous elements distributed throughout the tumor. The mucinous borderline tumor and mucinous carcinomas groups had similar proportions of positivity (mucinous borderline tumor: 53%, mucinous carcinomas: 39%). In the other tumor types, except for HGSC, there was only focal expression (5%–10%) or negativity for NE markers. HGSC showed high CD56 expression (in 26% of cases). Survival analysis was only performed for CD56 in HGSC as this was the only group with sufficient positive cases, and it showed no prognostic significance. Except for mucinous tumors, expression of NE markers in non-NE ovarian epithelial tumors is low. CD56 expression in HGSC occurs frequently but is without diagnostic or prognostic value.

Links

90125, large research infrastructures

Name: BBMRI-CZ III

Citovat

BÁRTŮ KENDALL, Michaela, Kristýna NĚMEJCOVÁ, Romana MICHÁLKOVÁ, Quang Hiep BUI, Jana DROZENOVÁ, Pavel FABIAN, Oluwole FADARE, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATĚJ, Gábor MÉHES, Adam ŠAFANDA, Naveena SINGH, Petr ŠKAPA, Zuzana ŠPŮRKOVÁ, Simona STOLNICU, Marián ŠVAJDLER, Sigurd F LAX, W Glenn MCCLUGGAGE and Pavel DUNDR. Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases. International Journal of Gynecological Pathology. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2024, vol. 43, No 2, p. 123-133. ISSN 0277-1691. Available from: https://dx.doi.org/10.1097/PGP.0000000000000962.

@article{2300437,
   author = {Bártů Kendall, Michaela and Němejcová, Kristýna and Michálková, Romana and Bui, Quang Hiep and Drozenová, Jana and Fabian, Pavel and Fadare, Oluwole and Hausnerová, Jitka and Laco, Jan and Matěj, Radoslav and Méhes, Gábor and Šafanda, Adam and Singh, Naveena and Škapa, Petr and Špůrková, Zuzana and Stolnicu, Simona and Švajdler, Marián and Lax, Sigurd F and McCluggage, W Glenn and Dundr, Pavel},
   article_location = {PHILADELPHIA},
   article_number = {2},
   doi = {http://dx.doi.org/10.1097/PGP.0000000000000962},
   keywords = {INSM1; Synaptophysin; Chromogranin; Immunohistochemistry; Ovarian Tumors},
   language = {eng},
   issn = {0277-1691},
   journal = {International Journal of Gynecological Pathology},
   title = {Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases},
   url = {https://journals.lww.com/intjgynpathology/Abstract/9900/Neuroendocrine_Marker_Expression_in_Primary.90.aspx},
   volume = {43},
   year = {2024}
}

TY  - JOUR
ID  - 2300437
AU  - Bártů Kendall, Michaela - Němejcová, Kristýna - Michálková, Romana - Bui, Quang Hiep - Drozenová, Jana - Fabian, Pavel - Fadare, Oluwole - Hausnerová, Jitka - Laco, Jan - Matěj, Radoslav - Méhes, Gábor - Šafanda, Adam - Singh, Naveena - Škapa, Petr - Špůrková, Zuzana - Stolnicu, Simona - Švajdler, Marián - Lax, Sigurd F - McCluggage, W Glenn - Dundr, Pavel
PY  - 2024
TI  - Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases
JF  - International Journal of Gynecological Pathology
VL  - 43
IS  - 2
SP  - 123-133
EP  - 123-133
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 02771691
KW  - INSM1
KW  - Synaptophysin
KW  - Chromogranin
KW  - Immunohistochemistry
KW  - Ovarian Tumors
UR  - https://journals.lww.com/intjgynpathology/Abstract/9900/Neuroendocrine_Marker_Expression_in_Primary.90.aspx
N2  - Expression of neuroendocrine (NE) markers in primary ovarian non-NE epithelial tumors has rarely been evaluated. The aim of our study was to evaluate the expression of the most widely used NE markers in these neoplasms and to determine any prognostic significance of NE marker expression. The cohort consisted of 551 primary ovarian tumors, including serous borderline tumors, low-grade serous carcinomas, high-grade serous carcinomas (HGSC), clear cell carcinomas, endometroid carcinomas, mucinous borderline tumors, and mucinous carcinomas. Immunohistochemical analysis was performed using antibodies against INSM1, synaptophysin, chromogranin, and CD56 on tissue microarray. Positivity for INSM1, synaptophysin, chromogranin, and CD56 was most frequently observed in mucinous tumors (48.7%, 26.0%, 41.5%, and 100%, respectively). The positivity for these NE markers was mostly restricted to nonmucinous elements distributed throughout the tumor. The mucinous borderline tumor and mucinous carcinomas groups had similar proportions of positivity (mucinous borderline tumor: 53%, mucinous carcinomas: 39%). In the other tumor types, except for HGSC, there was only focal expression (5%–10%) or negativity for NE markers. HGSC showed high CD56 expression (in 26% of cases). Survival analysis was only performed for CD56 in HGSC as this was the only group with sufficient positive cases, and it showed no prognostic significance. Except for mucinous tumors, expression of NE markers in non-NE ovarian epithelial tumors is low. CD56 expression in HGSC occurs frequently but is without diagnostic or prognostic value.
ER  -

BÁRTŮ KENDALL, Michaela, Kristýna NĚMEJCOVÁ, Romana MICHÁLKOVÁ, Quang Hiep BUI, Jana DROZENOVÁ, Pavel FABIAN, Oluwole FADARE, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATĚJ, Gábor MÉHES, Adam ŠAFANDA, Naveena SINGH, Petr ŠKAPA, Zuzana ŠPŮRKOVÁ, Simona STOLNICU, Marián ŠVAJDLER, Sigurd F LAX, W Glenn MCCLUGGAGE and Pavel DUNDR. Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases. \textit{International Journal of Gynecological Pathology}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{} WILKINS, 2024, vol.~43, No~2, p.~123-133. ISSN~0277-1691. Available from: https://dx.doi.org/10.1097/PGP.0000000000000962.

Detailed Information on Publication Record